{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:52:38Z","timestamp":1791823958948,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ejca.2020.02.025","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T12:22:53Z","timestamp":1585311773000},"page":"193-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Emergency presentations in patients treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"130","author":[{"given":"Tim","family":"Cooksley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Al-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.02.025_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.02.025_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.02.025_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.ejca.2020.02.025_bib4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.02.025_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejim.2017.09.025","article-title":"Acute Oncology Care: a narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors","volume":"45","author":"Knight","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejca.2020.02.025_bib6","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.02.025_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.52964\/AMJA.0647","article-title":"Problem-based review: immune-mediated complications of \u201ccheckpoint inhibitors\u201d for the acute physician","volume":"16","author":"Webb","year":"2017","journal-title":"Acute Med"},{"key":"10.1016\/j.ejca.2020.02.025_bib8","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"17","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2020.02.025_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1200\/JOP.2014.001248","article-title":"Impact of observation status on hospital use for patients with cancer","volume":"11","author":"Lipitz-Snyderman","year":"2015","journal-title":"J Oncol Pract"},{"issue":"2","key":"10.1016\/j.ejca.2020.02.025_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.52964\/AMJA.0755","article-title":"SAMBA18 report \u2013 a National Audit of acute medical care in the UK","volume":"18","author":"Lasserson","year":"2019","journal-title":"Acute Med"},{"issue":"6","key":"10.1016\/j.ejca.2020.02.025_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7861\/clinmedicine.12-6-501","article-title":"NEWSDIG: the National early warning score development and implementation group","volume":"12","author":"Jones","year":"2012","journal-title":"Clin Med"},{"issue":"1","key":"10.1016\/j.ejca.2020.02.025_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annemergmed.2018.04.019","article-title":"Adverse effects of immune checkpoint therapy in cancer patients visiting the Emergency Department of a comprehensive cancer center","volume":"73","author":"El Majzoub","year":"2019","journal-title":"Ann Emerg Med"},{"issue":"7","key":"10.1016\/j.ejca.2020.02.025_bib13","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"issue":"6","key":"10.1016\/j.ejca.2020.02.025_bib14","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.02.025_bib15","first-page":"3","article-title":"Emergency oncology: development, current position and future direction in the US and UK","volume":"25","author":"Cooksley","year":"2017","journal-title":"Support Care Canc"},{"key":"10.1016\/j.ejca.2020.02.025_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Canc"},{"issue":"24","key":"10.1016\/j.ejca.2020.02.025_bib17","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1002\/cncr.31789","article-title":"Emergency management of immune-related hypophysitis: collaboration between specialists is essential to achieve optimal outcomes","volume":"124","author":"Cooksley","year":"2018","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:48Z","timestamp":1760732868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920300988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":17,"alternative-id":["S0959804920300988"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.02.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emergency presentations in patients treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}